Korean Brokerages Cut Price Targets on LX International, Handsome and GC Biopharma

Three Seoul brokerages lowered their price targets in the space of two days after second-quarter results at the companies they cover came in below estimates: Eugene Investment & Securities on trading house LX International, Hanwha Investment & Securities on fashion group Handsome, and DAOL Investment & Securities on drugmaker GC Biopharma. The steepest disclosed cut came at Handsome, where Hanwha lowered its target from 37,000 won to 28,000 won — a reduction of roughly 24 percent.

Three Companies, Three Different Businesses

The revisions touched an unusually varied set of industries for a single stretch of the earnings calendar.

Eugene Investment & Securities kept its buy rating on LX International (KRX: 001120), the trading and resources arm of LX Group, but cut a target that had previously stood at 80,000 won after the company’s second-quarter performance fell short of the brokerage’s estimates.

Hanwha Investment & Securities took its target on Handsome, the fashion house within Hyundai Department Store Group, down to 28,000 won from 37,000 won, citing second-quarter operating profit that missed expectations.

DAOL Investment & Securities lowered its target on GC Biopharma (KRX: 006280), the plasma and vaccine specialist long known as Green Cross, from a prior 210,000 won, likewise pointing to quarterly results below what it had penciled in.

The Rating Stays, the Number Moves

Eugene’s decision to hold its buy call on LX International even while marking the stock down is characteristic of how Korean equity research communicates disappointment. Outright sell recommendations remain rare on the domestic sell side, so a target-price cut — especially one paired with an unchanged rating — is typically where an analyst’s revised view actually shows up. For investors reading these notes, the size of the cut matters more than the label attached to it: Hanwha’s roughly 24 percent reduction on Handsome implies a substantially weaker earnings trajectory than a rating change alone would convey.

Reading a Scattered Set of Misses

A commodities-exposed trader, an apparel retailer and a biopharmaceutical maker share little in the way of demand drivers, which suggests these disappointments are largely company-specific rather than evidence of a single macro shock working through the market. Even so, the timing is notable: the notes landed within the July–August reporting window, when analysts recalibrate full-year estimates on actual first-half numbers. Whether the pattern of downward revisions broadens as more Korean companies report their second-quarter results — or stays confined to isolated misses like these — will say more about the underlying health of corporate earnings than any one of the three cuts on its own.